An observational study in Lung Hydatid Cyst, sponsored by Abdullah Adiyaman. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 83 Years. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by Abdullah Adiyaman · Observational
This study aims to investigate the role of these laboratory findings in the differential diagnosis and management of pulmonary hydatid cyst (PHC) by examining the number of euzonophils, neutrophils, lymphocytes, platelets and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and systemic immune inflammatory index values in the peripheral blood of patients diagnosed with pulmonary hydatid cyst (PHC) in the preoperative period and post-operative 3rd month. Although we have extensive data on hydatid liver cysts, there is limited information in the literature on the laboratory values of patients with PHC. This study aims to provide more scientific basis for the diagnosis and management of PHC and is considered as an inexpensive, reproducible and easily calculable method to improve the accurate diagnosis and management of AKH in clinical practice.
Hydatid cyst of the lung (HCC) is a health problem caused by a small species of tapeworm called Echinococcus granulosus, a parasitic infection that can occur in humans and other mammals. Hydatid cysts are cysts caused by the larvae of the parasite. They most commonly form in the liver and lungs, but can also occur in other organs. E. granulosus lives in the intestines of animals and excretes them in their feces. Humans can get the eggs of this parasite through contact or under poor hygiene conditions. The ingested eggs hatch in the stomach and intestine and the larvae enter the bloodstream, then form cysts in various organs throughout the body.
Cystic echinococcosis is a disease in which a large group of patients live in conditions of material and social poverty. The disease has a widespread distribution worldwide and the regions with high disease prevalence are Southeast Europe, the Middle East, North, Central and East Asia and South America.
25 studies on the registry are indexed under Echinococcosis; 4 are open to participants now.
This study's planned enrollment of 54 is above the median of 45 across 18 observational studies indexed under Echinococcosis.
Browse Echinococcosis studies →This is the only study on the registry with Abdullah Adiyaman as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Peripheral blood results of patients hospitalized in the thoracic surgery clinic of S.B.Ü Van Training and Research Hospital due to hydatid cyst of the lung (surgery) will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
File screening and blood test results will be evaluated
Also known as: File screening and blood test results will be evaluated
Calculation of laboratory markers
euzonophil (10\^9/L) , neutrophil (10\^9/L), lymphocyte (10\^9/L), platelet (10\^3/uL) counts and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, systemic immune inflammatory index (SII = P × N/L) values calculated using these data in the peripheral blood results of patients diagnosed with pulmonary hydatid cyst (PHC) in the pre-operative period and post-operative 3rd month will be examined retrospectively.
Time frame: 2 monts
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Mar 2024, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.